Is Laronidase safe while breastfeeding?
Here is what NIH LactMed, the U.S. National Library of Medicine's authority on medicines and breastfeeding, reports about Laronidase. This is a summary of that source — not our own verdict.
Effects on the breastfed infant
A woman with mucopolysaccharidosis type I received intravenous laronidase 100 units/kg weekly for 28 doses during her 37-week pregnancy. She resumed therapy one week after delivery and breastfed her infant for 3 months. The infant had normal height and weight up to 12 months of age and showed normal development at 2.5 years of age. No adverse drug reactions were reported in the infant.[ 1 ]
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. A woman with mucopolysaccharidosis type I received intravenous laronidase 100 units/kg weekly during breastfeeding, beginning one week after delivery. Laronidase was undetectable (assay limits not specified) in breastmilk just before the infusion and 60 minutes after the infusion at 1 and 3 months postpartum.[ 1 ] Infant Levels. Relevant published information was not found as of the revision date.
Source: NIH LactMed (National Library of Medicine).
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.